(Adds details throughout)
Nov 22 (Reuters) - Lexicon Pharmaceuticals said on Friday it would reduce its workforce by about 60%, after the U.S. Food and Drug Administration noted deficiencies in its application seeking approval for its diabetes drug.
This comes days after a panel of advisers to the FDA voted against recommending the drug, sotagliflozin, as an add-on treatment to insulin therapy for managing blood glucose levels in adults with type 1 diabetes and chronic kidney disease.
Shares of the biopharma firm were down nearly 12% at 68 cents in premarket trading.
Lexicon said it will eliminate its commercial field team and stop promotional efforts for its approved heart failure treatment, Inpefa.
However, the company said it will continue to manufacture and make Inpefa available to patients and existing prescribers.
As part of the restructuring, Lexicon aims to reduce operating costs by $100 million in 2025.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。